摘要
目的：研究雷帕霉素（Rapamycin, Rapa）和凋亡素（TAT-apoptin, T-ap）联合应用对神经胶质瘤的治疗作用。方法用 MTT 实验比较 Rapa、 TAT-apoptin 单用和联合应用对 U87细胞增殖的影响； AO/EB 荧光染色与流式细胞仪检测对 U87细胞凋亡的影响；建立裸鼠 C6胶质瘤皮下移植模型,计算 Rapa、TAT-apoptin 单独及联合作用下的抑瘤率。结果 Rapa 与 TAT-apoptin 单独用药均能抑制 U87细胞的增殖,呈剂量依赖性,联合用药组细胞增殖率明显低于单独用药组（P ﹤0.05）；联合用药组凋亡状态比单独用药更明显,呈晚期凋亡形态,细胞凋亡率显著高于单独用药组（P ﹤0.01）；在体内实验中,联合用药组抑瘤率为65.5％,雷帕霉素与 TAT-凋亡素单独用药抑瘤率分别为29.59％,24.4％,前者比后者高1倍（P ﹤0.05）。结论 Rapa 与 TAT-ap 联合用药可增强对胶质瘤细胞增殖的抑制作用,促进胶质瘤细胞的凋亡,产生协同的抗肿瘤作用。
Objective To investigate the inhibitory effects of rapamycin in combination with TAT-apoptin on malignant glioma. Methods MTT assay was used to detect the proliferation rate of U87 cells treated by rapamycin alone or combined with TAT-apoptin. Cell apoptosis was detected by AO/ EB Fluorescence and Annexin V/ PI staining. C6 xenograft glioma models were constructed in nude mice, which were given injection of rapamycin alone or combined with TAT-apoptin. The effects of rapamycin alone or combined with TAT-apoptin on tumor growth were explored. Results Rapamycin and TAT-apoptin could separately inhibit the proliferation of U87 cells in a dose-depend-ent manner. The two drugs combined could significantly inhibit the cell proliferation when compared with single drug treatment （P ﹤ 0. 05）, and the apoptosis rate of U87 cells in the combined group was significantly increased when compared with that in the single drug group （P ﹤ 0. 01） . The rate of tumor inhibition was 65. 5% in combined group, about one fold higher than 29. 49% in rapamy-cin group and 24. 11% in T-apoptin. Conclusion Rapamycin in combination with TAT-apoptin can increase the inhibitory effects on the proliferation of glioma cells, promote the cell apoptosis and have synergistic anti-tumor effects.
出处
《医学分子生物学杂志》
CAS
2015年第2期69-74,共6页
Journal of Medical Molecular Biology
